Bluebird Bio (BLUE) Receives a Buy from J.P. Morgan

By Carrie Williams

In a report issued on January 14, Cory Kasimov from J.P. Morgan assigned a Buy rating to Bluebird Bio (BLUEResearch Report). The company’s shares closed last Monday at $98.04.

According to, Kasimov is a 4-star analyst with an average return of 7.2% and a 47.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Global Blood Therapeutics, and Alexion Pharmaceuticals.

Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $118.67.

See today’s analyst top recommended stocks >>

Based on Bluebird Bio’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $206 million. In comparison, last year the company had a GAAP net loss of $149 million.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.